Portland, OR -- (SBWIRE) -- 02/20/2018 -- T cell is a type of white blood cell, and plays an important role in cell-medicated immunity. Engineered T cells are genetically modified T cells, specifically altered for therapeutic actions against autoimmune diseases and various types of cancers. The engineered T cells are delivered into patient's body to reduce toxicity levels and restrict antigen escape (inability of immune system to respond to an infectious agent) for elimination of cancerous cells. The global engineered T cells market was valued at $145.97 million in 2016, and is estimated to reach at $2,124.02 million by 2023, registering a CAGR of 46.5% from 2017 to 2023.

For More Info, Get Sample : http://bit.ly/2o97W3X

Increase in of incidence of various types of cancers and autoimmune diseases is projected to drive the growth of the engineered T cells market. In addition, advantages offered by engineered T cells therapies over traditional cancer treatments such as chemotherapy, high technological advancements, and increase access to medical insurance are expected to boost the market growth. However, high cost associated with T cells therapies and lack of awareness about T cells therapies hinder the growth of this market.

The engineered T cells market is segmented based on type, application, end user, and geography. On the basis of type, the market is categorized into chimeric antigen receptor (CAR) modified T cells, tumor infiltrating lymphocytes (TIL), and T cells receptor (TCR) modified T cells. By application, it is classified into lung cancer, breast cancer, colorectal cancer, melanoma, leukemia, and other applications. Depending on end user, it is fragmented into hospitals, cancer research centers, and clinics. Geographically, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

KEY MARKET BENEFITS FOR STAKEHOLDERS

- The study provides an in-depth analysis of the global engineered T-cells market and the current trends and future estimations to elucidate the imminent investment pockets.
- It presents a quantitative analysis of the market from 2016 to 2023 to enable stakeholders to capitalize on the prevailing market opportunities.
- Extensive analysis of the market based on end user assists to understand the trends in the industry.
- Key market players and their strategies are thoroughly analyzed to understand the competitive outlook of the market.

KEY MARKET SEGMENTS

By Type

- Chimeric Antigen Receptor (CAR)
- Tumor Infiltrating Lymphocytes (TIL)
- T-cell Receptor (TCR)

Enquire About Report : http://bit.ly/2BZlhpb

By Application

- Lung Cancer
- Breast Cancer
- Colorectal Cancer
- Melanoma
- Leukemia
- Others

By End User

- Hospitals
- Cancer Research Centers
- Clinics

By Region

- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- Japan
- China
- Australia
- India
- South Korea
- Taiwan
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Turkey
- Saudi Arabia
- South Africa
- Rest of LAMEA

Also Request For Discount : http://bit.ly/2BwLDO3

KEY PLAYERS PROFILED IN THE REPORT

- Autolus Limited
- Bellicum Pharmaceuticals, Inc.
- Cell Medica
- Elli Lilly and Company
- Gilead Sciences, Inc.
- Juno Therapeutics
- Novartis AG
- Oxford Biomedica
- Pfizer Inc.
- Precision Bioscience

The other players in the value chain include (profiles not included in the report)

- Redmile Group
- Seeking Alpha
- Unum Therapeutics Inc.

Table Of Content

- CHAPTER 1 INTRODUCTION
- CHAPTER 2 EXECUTIVE SUMMARY
- CHAPTER 3 MARKET OVERVIEW
- CHAPTER 4 ENGINEERED T CELLS MARKET, BY TYPE
- CHAPTER 5 ENGINEERED T CELLS MARKET, BY APPLICATION
- CHAPTER 6 ENGINEERED T CELLS MARKET, BY END USER
- CHAPTER 7 ENGINEERED T CELLS MARKET, BY REGION
- CHAPTER 8 COMPANY PROFILES

We have a large database of quality and precise market research reports that will be very beneficial for your organization. Reports that we sell our authentic in nature and from reputed publishers, hence it can definitely help you with your growth opportunities. Research Beam will always make sure to bring most ethical and high quality reports. We value your relationship with us and look forward for a long term relation.

Contact Us
Global Head Quarters
5933 NE Win Sivers Drive,
#205, Portland, OR 97220
United States
+1 (800) 910-6452
help@researchbeam.com